Llwytho...
Objective and subjective measures of dalfampridine efficacy in clinical practice
BACKGROUND: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patie...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Mult Scler J Exp Transl Clin |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6077903/ https://ncbi.nlm.nih.gov/pubmed/30090641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318786742 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|